Ammad Khan

Co-Founder, Chief Executive Officer

Ammad is CEO and Co-Founder of IrisVision, a game-changing smart headset that uses utilizes proprietary software leveraging the power of a smartphone and XR devices to enable people with impaired vision to see clearly and live more independent lives. With experience spanning a
variety of companies at the intersection of medicine and technology, he leads the company's mission to enable millions of people with severely low vision to, “see clearly and live fully.”

Through strategic partnerships with Samsung, Johns Hopkins School of Medicine, Stanford Eye Institute to name a few, the company's technology is redefining what is possible in the field of vision care for the greatest social impact.

Dr. Frank Werblin

Co-Founder, Chief Scientist

IrisVision was Co-founded by Dr. Frank Werblin, an MIT graduate, Guggenheim Fellow, and professor at UC Berkeley. Dr. Werblin is renowned for his scientific contributions to our understanding of retinal functioning. He has dedicated his life to innovating, developing and delivering an affordable non-invasive solution for millions of people with low vision.

With insight from research partners at Stanford, Johns Hopkins, UC Berkeley, UPMC, The Chicago Lighthouse for the Blind, and other institutions contributing to low vision science, IrisVision is the realization of that lifetime of work. He is dedicated to pushing the boundaries of low vision solutions by continuing to expand the relationship with top vision scientists and technology powerhouses like Samsung.

Advisory Board

Dr. Jeffrey Goldberg
Professor and Chair of Ophthalmology,
Byers Eye Institute at Stanford University

Dr. Jeffrey Goldberg is Professor and Chair of Ophthalmology at the Byers Eye Institute at Stanford University. His clinical effort is focused on patients in need of medical or surgical intervention for glaucoma and other retinal and optic nerve diseases, as well as cataract. He was elected in 2010 to the American Society of Clinical Investigation, an honorary society of physician scientists. He directs an NIH-funded research laboratory and has developed significant expertise with implementing FDA IND clinical trials for optic nerve neuroprotection and regeneration. His goal is to translate scientific discoveries to patient therapies.

Dr. Bob Massof
Professor of Ophthalmology, Johns
Hopkins School of Medicine

Dr. Massof, Ph.D., is a professor of ophthalmology and professor of neuroscience at the Johns Hopkins University School of Medicine. He is founder and director of the Lions Vision Research and Rehabilitation Center at the Wilmer Eye Institute. He also entered a collaborative project with the National Aeronautics and Space Administration (NASA), the Veterans Administration Rehabilitation Research and Development Service, and private companies and investors to develop, test, and commercialize the Low Vision Enhancement System (LVES), the first head-mounted video system designed to enhance and compensate for low vision.

Dr. Mark Blumenkranz
Surgeon and Entrepreneur, Professor &
Former chair of Ophthalmology, Stanford University

Dr. Blumenkranz, M.D., MMS, is HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University. He is a past President of the American University Professors of Ophthalmology (AUPO), a past President of the Retina Society and the Macula Society and a member of the Steering Committee of the Audacious Goals Initiative of the NEI. He was a co-founder and director of Oculeve, a dry eye company employing a neuro-modulatory approach to therapy, which was acquired by Allergan in August of 2015.

Dr. David Myung
Assistant Professor of Ophthalmology
Stanford University, Physician and
Surgeon — VA Health Care System

Dr. Myung is an Assistant Professor of Ophthalmology at the Byers Eye Institute at Stanford and, by courtesy, of Chemical Engineering. He is a board-certified ophthalmologist and attending physician at the VA Palo Alto Health Care System specializing in cataract and corneal surgery and external diseases of the eye, and is Co-Director of the Ophthalmic Innovation Program, a project-based fellowship in the development and regulatory science of new eye-care technologies, as well as the Director of Teleophthalmology at the Byers Eye Institute.

Dr. Roger Goldberg

Dr. Goldberg is board certified by the American Board of Ophthalmology, and is an active member of the American Society of Retinal Specialists and the American Academy of Ophthalmology. He serves as a Reviewer for the AJO and Retina, and has lectured at national and international meetings. He has been an investigator in over 20 clinical trials for age-related macular degeneration, retinal vein occlusion, diabetic retinopathy, and vitreomacular adhesion. His surgical interests include complex retinal detachment repair, endoscopic surgery, and complications of cataract surgery.

Dr. Erich Horn
Advisor & Investor
Ophthalmologist, University of Florida

Dr. Horn, M.D., MBA, is a board-certified ophthalmologist. He serves as an associate professor in the department of ophthalmology at the University of Florida College of Medicine. He is a member of the American Academy of Ophthalmology, Florida Medical Association, Association for Research and Vision and the American Society of Cataract and Refractive Surgery.